We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Oral Chemotherapy with Idarubicin plus Cyclophosphamide in Advanced Breast Cancer.
- Authors
Pronzato, P.; Bertelli, G.; Amoroso, D.; Pennucci, C.; Gardin, G.; Guido, T.; Rosso, P.
- Abstract
An oral chemotherapy schedule based on idarubicin and cyclophosphamide was evalutated in 31 advanced breast cancer patients. Out of 27 patients evaluable for response, 1 (3.7%) achieved a complete response and 5 (18.5%) a partial response, with an objective response rate of 22.2% (95% confidence limits 8.6-42.3%). The median time to progression was 7 months (range 3-12). Fourteen patients (51.9%) showed a disease stabilization, and 7 progressed (25.9%). Toxicity was mild. Considering the low response rate, but also the advantages of oral chemotherapy and the mild toxicity observed, oral idarubicin plus cyclophosphamide can be considered as a second-choice regimen in advanced breast cancer. Copyright © 1991 S. Karger AG, Basel
- Publication
Chemotherapy (0009-3157), 1991, Vol 37, Issue 6, p449
- ISSN
0009-3157
- Publication type
Article
- DOI
10.1159/000238893